These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12628045)

  • 1. Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.
    Varga J
    Curr Rheumatol Rep; 2003 Apr; 5(2):145-6. PubMed ID: 12628045
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience].
    Ahmadi-Simab K; Lamprecht P; Hellmisch B; Gross WL
    Z Rheumatol; 2004 Dec; 63(6):495-7. PubMed ID: 15605216
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
    Musch A
    Med Monatsschr Pharm; 2006 Jul; 29(7):242-5. PubMed ID: 16866076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolution of severe digital ulceration during a course of Bosentan therapy.
    Snyder MJ; Jacobs MR; Grau RG; Wilkes DS; Knox KS
    Ann Intern Med; 2005 May; 142(9):802-3. PubMed ID: 15867420
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long-term therapy with endothelin-1 antagonist for pulmonary hypertension secondary to systemic sclerosis].
    Shalev L; Langevitz P; Zandman-Goddard G
    Harefuah; 2008 Apr; 147(4):287-9, 376. PubMed ID: 18686806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
    Shetty N; Derk CT
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension.
    Hamaguchi Y; Fujimoto M; Hasegawa M; Matsushita T; Takehara K
    J Dermatol Sci; 2009 Jul; 55(1):66-7. PubMed ID: 19342201
    [No Abstract]   [Full Text] [Related]  

  • 9. [Blockade of endothelin receptor with bosentan--a new principle of treatment in pulmonary arterial hypertension].
    Nielsen-Kudsk JE
    Ugeskr Laeger; 2003 Jul; 165(29):2891-4. PubMed ID: 12908360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
    Nishibu A; Sakai E; Oyama N; Yamamoto T
    Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pulmonary arterial hypertension related to systemic sclerosis in 2008].
    Agard C; Haloun A; Hamidou MA
    J Mal Vasc; 2009 Feb; 34(1):7-15. PubMed ID: 19081217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosentan in systemic sclerosis.
    Heresi GA; Minai OA
    Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade.
    Sharma S; Kashour T; Philipp R
    Tex Heart Inst J; 2005; 32(3):405-10. PubMed ID: 16392231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review on bosentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Serasli E; Michaelidis V; Kosmas A; Antoniadou M; Tsara V
    Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):184-95. PubMed ID: 20874675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.
    Humbert M; Cabane J
    Rheumatology (Oxford); 2003 Jan; 42(1):191-3. PubMed ID: 12509640
    [No Abstract]   [Full Text] [Related]  

  • 17. Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension.
    Hughes R; Jais X; Suntharalingam J; Humbert M; Parent F; Simonneau G; Pepke-Zaba J
    Expert Opin Pharmacother; 2006 Jun; 7(9):1133-8. PubMed ID: 16732700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis.
    Oldfield V; Lyseng-Williamson KA
    Am J Cardiovasc Drugs; 2006; 6(3):189-208. PubMed ID: 16780392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.
    Hachulla E; Coghlan JG
    Ann Rheum Dis; 2004 Sep; 63(9):1009-14. PubMed ID: 15308510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.